Company intelligence / Profile preview

Blueberry Therapeutics

Alderley Edge, Cheshire, United Kingdomblueberrytherapeutics.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

BB2603, a novel topical terbinafine antifungal product using nanotechnology, met primary and secondary endpoints in a Phase 2b trial for onychomycosis. The trial showed an 83.3% response rate at Week 16 after three months of treatment—significantly higher than placebo—with sustained efficacy at Week 52. Safety profile was excellent with no systemic exposure or serious adverse events reported. Planning for Phase 3 trials is underway.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Nanomedicinesnanopolymer drug delivery technologytopical small molecules (notably terbinafine)
Industry: Biotech

Drug pipeline

5 assets

BB2603

4 more assets in the full pipeline.

Request access →

Partnerships

CMS (China Medical System Holdings) – partnership to commercialize BB2603 in ChinaOther partners/investors include Northern Powerhouse Investment Fund, Medical Incubator Japan, China Medical Venture Investment, A&B (HK) Company

Beyond the preview

Go deeper on Blueberry Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blueberry Therapeutics.

Explore the full profile